KRAS and cancer: Treating KRAS-mutant cancers with G12Ci results in the feedback activation of the MAK pathway, which modulates ferroptosis in cancer cells, thus suggesting that the MAPK-SOX2 axis is an essential target for the modulation of ferroptosis in G12Ci-resistant tumors via the regulation of intracellular GSH synthesis [131].